Tirzepatide (Mounjaro) UAE: Complete Guide to Dosage, Side Effects, and Where to Buy in Dubai (2026)
Tirzepatide (Mounjaro) UAE: Complete Guide to Dosage, Side Effects, and Where to Buy in Dubai (2026)
Tirzepatide is the first dual GIP and GLP-1 receptor agonist to reach clinical use — and in the UAE, demand for Mounjaro has surged as residents discover it produces nearly 50% more weight loss than Ozempic. This guide covers everything UAE residents need to know: SURMOUNT-1 trial data, the complete titration protocol, side effect management, Dubai pricing in AED, and how to source it in 2026.
Table of Contents
- What Is Tirzepatide?
- How It Works: Dual GIP + GLP-1 Mechanism
- SURMOUNT-1 Trial Results
- Complete Dosing Protocol
- Side Effects and How to Manage Them
- Who Should Use Tirzepatide?
- Tirzepatide vs Semaglutide (Ozempic/Wegovy)
- Tirzepatide vs Retatrutide
- Legal Status in UAE and Dubai
- Price in Dubai and Abu Dhabi (AED Guide)
- Injection Technique Step-by-Step
- Using Tirzepatide During Ramadan
- Frequently Asked Questions
What Is Tirzepatide?
Tirzepatide is a once-weekly injectable medication developed by Eli Lilly and sold under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It belongs to a class of drugs known as incretin mimetics — molecules that mimic the natural gut hormones your body releases after eating to regulate blood sugar, appetite, and digestion.
What makes tirzepatide exceptional is its dual mechanism. Unlike older GLP-1 agonists such as semaglutide (Ozempic) that target only one receptor, tirzepatide activates two: the GLP-1 receptor (glucagon-like peptide-1) and the GIP receptor (glucose-dependent insulinotropic polypeptide). This dual agonism produces weight loss results significantly beyond what single-target drugs achieve.
The drug was first approved by the FDA in May 2022 for type 2 diabetes and in November 2023 for chronic weight management (as Zepbound). In the UAE, tirzepatide is regulated by MOHAP and the Dubai Health Authority, making it legally accessible with a valid prescription from a licensed UAE physician.
Key Facts at a Glance
- Generic name: Tirzepatide
- Brand names: Mounjaro (diabetes), Zepbound (weight loss)
- Developer: Eli Lilly
- Mechanism: Dual GIP + GLP-1 receptor agonist
- Administration: Once-weekly subcutaneous injection
- Doses available: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg
- Max weight loss (trial): Up to 22.5% of body weight
- UAE legal status: MOHAP and DHA approved — requires prescription
How It Works: Dual GIP + GLP-1 Mechanism
To understand why tirzepatide outperforms its predecessors, you need to understand the two hormone systems it activates simultaneously.
The GLP-1 Pathway
GLP-1 (glucagon-like peptide-1) is released from intestinal L-cells after eating. It stimulates the pancreas to secrete insulin (lowering blood sugar), suppresses the release of glucagon (which would otherwise raise blood sugar), and — critically for weight loss — slows gastric emptying so you feel full longer. GLP-1 also acts on the hypothalamus to reduce hunger signals. Semaglutide (Ozempic, Wegovy) targets only this pathway and produces 14–15% weight loss.
The GIP Pathway
GIP (glucose-dependent insulinotropic polypeptide) is released from intestinal K-cells and was historically thought to be less important for weight control. More recent research has revealed that GIP receptor activation in adipose tissue and the central nervous system has significant metabolic effects — enhancing energy expenditure, reducing fat storage, and amplifying the weight loss signals initiated by GLP-1 activation. When both pathways are activated together, the effects are synergistic rather than merely additive.
Why the Dual Mechanism Matters
The combination of GIP and GLP-1 agonism creates three distinct advantages over GLP-1-only drugs:
- Greater weight loss magnitude — 15–22.5% vs 14.9% for semaglutide
- Better GI tolerability — GIP co-activation appears to partially offset the nausea caused by GLP-1 activation
- Superior metabolic improvements — larger reductions in waist circumference, triglycerides, HbA1c, and blood pressure vs comparable GLP-1 drugs
At a molecular level, tirzepatide is a 39-amino-acid peptide with a fatty acid chain that extends its half-life to approximately 5 days, enabling the once-weekly dosing schedule. This long half-life means consistent blood levels throughout the week without the peaks and troughs associated with shorter-acting drugs.
SURMOUNT-1 Trial Results: The Clinical Evidence
The foundation of tirzepatide's credibility is the SURMOUNT-1 Phase 3 clinical trial — one of the most rigorous obesity treatment studies ever conducted. Published in the New England Journal of Medicine in 2022, SURMOUNT-1 enrolled 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with at least one weight-related comorbidity). Participants did not have type 2 diabetes. The mean baseline weight was 104.8 kg with a mean BMI of 38.0.
Participants received weekly subcutaneous injections of tirzepatide at 5mg, 10mg, or 15mg, or placebo, for 72 weeks. All participants received lifestyle counselling. The results were remarkable:
| Dose | Mean Weight Loss (%) | Mean Weight Lost (kg) | ≥5% Weight Loss | ≥15% Weight Loss | ≥20% Weight Loss |
|---|---|---|---|---|---|
| Tirzepatide 5mg | 15–16% | ~16 kg | 85% | ~73% | 30% |
| Tirzepatide 10mg | 20–21% | ~21 kg | 89% | ~85% | 50% |
| Tirzepatide 15mg | 21–22.5% | ~24 kg | 91% | ~88% | 57% |
| Placebo | 2.4% | ~2.5 kg | 35% | 3% | <1% |
All differences versus placebo were statistically significant (p<0.001). The 15mg dose achieved an average weight reduction that rivals bariatric surgery outcomes, which typically produces 25–30% total body weight loss.
Body Composition Changes
A critical DXA substudy (n=160) published in 2025 examined what type of weight was being lost. Tirzepatide reduced total body weight by 21.3%, fat mass by 33.9%, and lean mass by 10.9% — compared to placebo reductions of 5.3%, 8.2%, and 2.6% respectively. Approximately 75% of the weight lost was fat mass, with 25% lean mass. This ratio is consistent across different subgroups (sex, age, starting weight) and is broadly comparable to other GLP-1 drugs, though the absolute fat loss is much greater.
This matters for UAE residents who are concerned about losing muscle while losing weight: pairing tirzepatide with resistance exercise and adequate protein intake (1.6–2.0g/kg body weight) can help preserve lean mass during the weight loss phase.
Waist Circumference and Metabolic Markers
Beyond the scale, SURMOUNT-1 documented substantial improvements in cardiovascular risk markers:
- Waist circumference reduced by 14–18.5 cm (vs 4 cm on placebo)
- Systolic blood pressure reduced by 6–8 mmHg
- Triglycerides reduced by 24–28%
- HDL cholesterol increased by 7–10%
- HbA1c (even in non-diabetics) reduced by 0.4–0.5%
Long-Term Data and Weight Maintenance
SURMOUNT-4 (the extension study) demonstrated that continuing tirzepatide maintained weight loss: participants who stayed on the drug lost an additional 5.5% weight between weeks 36 and 88, while those switched to placebo regained an average of 14% of body weight. This confirms that tirzepatide requires ongoing use for sustained results — a critical conversation to have with your physician before starting.
Complete Dosing Protocol
Tirzepatide's titration schedule was specifically designed to minimise gastrointestinal side effects during the early weeks of treatment. The key principle is never escalate faster than every 4 weeks. Escalating too quickly is the primary cause of severe nausea and dropout.
| Week | Dose | Phase | What to Expect |
|---|---|---|---|
| Weeks 1–4 | 2.5mg | Introduction | Body adapts to GIP/GLP-1 signalling. Mild appetite suppression. Minimal side effects. |
| Weeks 5–8 | 5mg | Early active loss | Noticeable appetite reduction. First significant weight loss. Some GI adjustment. |
| Weeks 9–12 | 7.5mg | Active loss | Strongest appetite suppression begins. Weight loss accelerates. GI side effects peak then settle. |
| Weeks 13–16 | 10mg | Active loss | High weight loss phase. Many users maintain 10mg as their final dose. |
| Weeks 17–20 | 12.5mg | Escalation (optional) | Only if well-tolerated at 10mg and weight loss has plateaued. |
| Week 21+ | 15mg | Maintenance (max dose) | Maximum studied dose. Reserved for those needing greater weight loss who tolerate 12.5mg well. |
What to Do If You Cannot Tolerate a Dose
If nausea, vomiting, or diarrhea at a new dose is disruptive and persists beyond 4 weeks, do not force escalation. Instead:
- Remain at the lower dose for an additional 4 weeks
- If symptoms persist beyond 8 weeks total, discuss with your physician whether to step back one dose
- Never stop tirzepatide abruptly without medical guidance — gradual discontinuation avoids rebound hunger
Maintenance Phase
Once your target weight or maximum tolerated dose is reached, you enter a maintenance phase. The dose stays constant. Some individuals eventually reduce dose under physician guidance after achieving significant weight loss, though SURMOUNT-4 data shows weight regain is the primary risk. Most people on tirzepatide for weight management use it indefinitely, similar to blood pressure or cholesterol medication.
Reconstituting Research-Grade Tirzepatide (Peptide Vials)
Research-grade tirzepatide supplied by peptide vendors like Core Sup comes as a lyophilised (freeze-dried) powder. To prepare it for injection:
Side Effects and How to Manage Them
Tirzepatide's side effects are predominantly gastrointestinal and occur because GLP-1 receptor activation slows gastric emptying — a feature that causes weight loss but also produces nausea in some users. Understanding this mechanism helps you manage symptoms rather than simply enduring them.
| Side Effect | Incidence (5–15mg) | Placebo | Typical Timing |
|---|---|---|---|
| Nausea | 25–28% | 8% | Weeks 1–4 of each escalation; usually resolves |
| Diarrhea | 19–23% | 8% | Variable; may be intermittent throughout |
| Constipation | 11–17% | 7% | More common in early weeks |
| Vomiting | 8–10% | 2% | Peaks during escalation phases |
| Decreased appetite | Very common | Low | Ongoing — this is the desired effect |
| Injection site reactions | 3–5% | Similar | Any time — rotate injection sites |
| Gallbladder events | 2–4% | Similar | Usually asymptomatic; monitor if history |
| Discontinuation due to AEs | 4–7% | 3% | Mainly GI; in first 12 weeks |
Practical Tips to Minimise Nausea
- Inject at night before bed — You sleep through the worst of the first-day nausea after each new dose
- Eat smaller portions — Tirzepatide slows gastric emptying; large meals become uncomfortable faster
- Avoid high-fat and fried foods — These are harder to digest with slowed gastric motility
- Stay hydrated — Essential, especially in Dubai's climate; aim for 2.5–3L daily
- Avoid escalating during stressful periods — Travel, Ramadan, or other health challenges: wait for a stable week
- Ginger tea or ginger chews — Evidence-backed natural remedy for drug-induced nausea
Serious Side Effects to Monitor
While rare, the following warrant immediate medical attention:
- Pancreatitis — Persistent severe abdominal pain radiating to the back; stop tirzepatide and seek medical care
- Thyroid tumours — Not documented in human trials at therapeutic doses but carries a class warning based on rodent data; avoid in patients with personal or family history of medullary thyroid carcinoma (MTC)
- Severe hypoglycaemia — Rare in non-diabetics but possible; more relevant if combining with other diabetes medications
- Allergic reactions — Rash, swelling, difficulty breathing after injection; discontinue immediately
Who Should Use Tirzepatide?
Tirzepatide is appropriate for adults who meet one or more of the following criteria:
Good Candidates for Tirzepatide
- BMI ≥30 (obesity) seeking meaningful, sustained weight loss
- BMI ≥27 with at least one comorbidity — type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea
- Adults with type 2 diabetes seeking better glycaemic control alongside weight loss
- Individuals who have tried diet and exercise without achieving adequate results
- Ozempic users who have plateaued and want a more potent option
- Anyone who wants to avoid bariatric surgery but needs surgical-level results
Who Should Avoid Tirzepatide
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- History of pancreatitis
- Pregnancy or breastfeeding
- Under 18 years of age
- Severe gastrointestinal disease (gastroparesis)
- Known hypersensitivity to tirzepatide
If you have type 1 diabetes, kidney disease, or liver disease, tirzepatide may still be appropriate but requires careful physician oversight and potential dose adjustments.
Tirzepatide vs Semaglutide (Ozempic/Wegovy): Head-to-Head Comparison
Most UAE residents asking about tirzepatide are already familiar with semaglutide — either through their own use of Ozempic for diabetes or Wegovy for weight loss, or through the extensive media coverage of the Ozempic shortage. Here is how they compare directly:
| Factor | Tirzepatide (Mounjaro) | Semaglutide (Ozempic/Wegovy) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 agonist only |
| Max weight loss (trial) | 22.5% at 72 weeks Better | 14.9% at 68 weeks |
| HbA1c reduction (T2D) | –2.0–2.3% | –1.5–1.8% |
| GI side effects | Nausea 25–28% Similar | Nausea 20–44% |
| Dosing schedule | Once weekly, 2.5mg → 15mg | Once weekly, 0.25mg → 2.4mg |
| Administration | KwikPen auto-injector | FlexPen or auto-injector |
| UAE availability | Available at clinics + pharmacies | Intermittent shortage 2023–2025 |
| Price in UAE (monthly) | 2,900–4,299 AED | ~1,600–2,800 AED (when available) |
| Cardiovascular evidence | SURMOUNT-MMO ongoing | FLOW trial: 20% CV event reduction |
When to Consider Switching from Ozempic to Mounjaro
If you are currently on semaglutide, switching to tirzepatide is a reasonable conversation to have with your physician if:
- You have plateaued at your current semaglutide dose and are not at your target weight
- You tolerate semaglutide well (suggesting you will tolerate tirzepatide similarly)
- Your insurance or budget can accommodate the cost difference
- You want the maximal available weight loss from an approved drug
When switching, the general approach is to allow 1 week after your last semaglutide dose before starting tirzepatide at 2.5mg (the lowest titration dose), then follow the standard escalation schedule. Never take both simultaneously.
Tirzepatide vs Retatrutide: Which Is More Powerful?
Retatrutide is the next generation beyond tirzepatide — a triple agonist that adds glucagon receptor activation on top of GIP and GLP-1. The additional glucagon pathway increases energy expenditure and fat oxidation in ways that dual agonism cannot achieve alone.
| Factor | Tirzepatide | Retatrutide |
|---|---|---|
| Mechanism | Dual: GIP + GLP-1 | Triple: GLP-1 + GIP + Glucagon |
| Trial weight loss | 22.5% (Phase 3, 72 wks) | 24.2% (Phase 2, 48 wks) Higher |
| Regulatory status | FDA approved (Mounjaro, Zepbound) | Phase 3 trials ongoing — research compound |
| UAE availability | MOHAP/DHA approved, prescription | Research compound — available via suppliers |
| Price at Core Sup | KwikPen 10mg: $542 | Triple G 5mg: $112.65 / 10mg: $286 |
| Injection device | Pre-filled auto-injector pen | Reconstituted vial + syringe |
| Best for | Established option with long-term safety data | Maximum weight loss, experienced users |
For most UAE residents beginning their weight loss journey, tirzepatide is the more appropriate starting point — it has full FDA approval, extensive long-term safety data from SURMOUNT trials, and is available through licensed UAE clinics with medical oversight. Retatrutide is increasingly chosen by individuals who have already used tirzepatide, want to maximise fat loss, and are comfortable with research compound protocols.
Mounjaro KwikPen Available at Core Sup UAE
Original Mounjaro KwikPen in 10mg and 15mg doses — plus research-grade retatrutide for those ready to upgrade. Discreet UAE delivery with same-day dispatch from Dubai.
Legal Status in the UAE and Dubai
Tirzepatide is fully legal in the UAE. It is regulated and approved by MOHAP (Ministry of Health and Prevention) at the federal level and by the Dubai Health Authority (DHA) and Department of Health Abu Dhabi (DoH) at the emirate level. UAE approval covers both the Mounjaro formulation (type 2 diabetes) and the Zepbound formulation (chronic weight management).
Prescription Requirements
In the UAE, tirzepatide requires a valid prescription from a UAE-licensed physician. The prescription process typically involves:
- Initial consultation (in-person or video call with a DHA/DoH-licensed doctor)
- Assessment of BMI, relevant comorbidities, and contraindications
- Issuance of prescription — typically valid for 3–6 months
- Purchase from a licensed pharmacy or clinic using the prescription
Travelling Within GCC With Tirzepatide
If you are travelling between UAE, Saudi Arabia, Kuwait, or Bahrain with tirzepatide:
- Carry your original prescription and any medical documentation
- Keep medication in original packaging with pharmacy label
- Store in a medical-grade cooling pouch for flights (tirzepatide must be kept at 2–8°C)
- Check destination country's import regulations — Saudi Arabia and Kuwait have different prescription rules
Research-Grade Tirzepatide: A Note on Regulatory Status
Research-grade tirzepatide peptide (sold as raw lyophilised powder for reconstitution) occupies a distinct regulatory category from the pharmaceutical Mounjaro/Zepbound pen. As an unprocessed research compound without a finished pharmaceutical designation, it does not fall under the same prescription drug regulations. This is why suppliers like Core Sup can provide it without requiring a prescription. Users should be aware that research-grade compounds do not carry the same quality guarantees as pharmaceutical-grade products unless they are sourced from reputable suppliers with third-party Certificate of Analysis (CoA) documentation.
Price in Dubai and Abu Dhabi: Complete AED Guide (2026)
Tirzepatide pricing in the UAE varies significantly by source, dose, and whether the price includes clinical services. Here is a current breakdown based on 2026 market data:
Mounjaro at UAE Clinics (Branded Pharmaceutical)
| Dose | Monthly Cost (AED) | Notes |
|---|---|---|
| 2.5mg (starting dose) | 1,500–2,999 AED | Starting/titration phase — 4 weeks |
| 5mg | 2,699–3,499 AED | Some clinics include diet plan |
| 7.5mg | 2,900–3,999 AED | Active weight loss phase |
| 10mg | 2,900–4,299 AED | Most common maintenance dose |
| 15mg (max dose) | 3,500–4,999 AED | Highest studied dose |
Most UAE clinics bundle the medication price with a consultation fee and 1–2 follow-up appointments. Standalone pharmacy purchase (Life Pharmacy, Aster, Boots) without a clinic bundle tends to be at the higher end of the price range per dose.
Research-Grade Tirzepatide via Core Sup
For those comfortable with peptide vial reconstitution and who do not require the pharmaceutical pen format, research-grade tirzepatide from Core Sup offers a cost-effective alternative:
| Product | Price (USD) | Approx AED | Notes |
|---|---|---|---|
| Mounjaro KwikPen 10mg | $542 | ~1,990 AED | Original Eli Lilly pharmaceutical pen |
| Mounjaro KwikPen 15mg | $542 | ~1,990 AED | Original Eli Lilly pharmaceutical pen |
| Retatrutide (Triple G) 5mg | $112.65 | ~414 AED | Research-grade vial, with CoA |
| Retatrutide 10mg | $286.00 | ~1,050 AED | Research-grade vial, with CoA |
AED conversions approximate at 3.67 USD/AED. Prices correct as of March 2026.
UAE GLP-1 Market Context
The UAE GLP-1 market is forecasted to grow at a 13.2% compound annual growth rate between 2025 and 2030 (MedicaPharma, 2025). The Ozempic shortage of 2023–2024, which forced the UAE Ministry of Health to restrict semaglutide prescriptions to confirmed diabetics only, accelerated the shift toward tirzepatide as the preferred GLP-1 class medication. By 2025, supply had stabilised, but the event underscored the UAE's position as a premium market for metabolic medications.
Injection Technique Step-by-Step
Correct injection technique improves efficacy and reduces injection site reactions.
Storage in Dubai's Climate
Tirzepatide must be stored at 2–8°C (standard refrigerator). In Dubai's climate, the following precautions matter:
- Never leave tirzepatide in a car — even in winter, parked cars can exceed 30°C within minutes
- Use an insulated medication pouch with ice packs for transport
- If briefly brought to room temperature (≤30°C), tirzepatide is stable for up to 21 days — but this window should not be used routinely
- Never freeze tirzepatide — freezing destroys the peptide structure and renders it ineffective
Using Tirzepatide During Ramadan
Fasting during Ramadan is a significant consideration for UAE residents using tirzepatide. The key concerns are nausea during daylight hours, adequate hydration, and hypoglycaemia risk for those also managing diabetes.
Practical Ramadan Protocol
- Injection timing: Shift your weekly injection to Iftar (breaking of the fast). This means nausea, if any, occurs during evening hours when you can eat small amounts and hydrate
- Hydration: Priority between Iftar and Suhoor. Aim for 2–2.5L of fluid during non-fasting hours. Dehydration amplifies tirzepatide's GI side effects
- Suhoor composition: Focus on protein-rich, slow-digesting foods. Avoid large fatty meals at Suhoor — tirzepatide's slowed gastric emptying means these will still be partially in your stomach at midday
- Dose considerations: Some physicians recommend temporarily pausing dose escalation during Ramadan — maintaining rather than increasing dose reduces the risk of nausea while fasting
- For diabetics on tirzepatide: Blood glucose monitoring is essential; fasting lowers requirements and tirzepatide's insulin-stimulating effects can cause hypoglycaemia if not adjusted. Consult your endocrinologist before Ramadan begins
- Gentle exercise: Light exercise after Taraweeh prayers (late evening) is preferable to midday exercise when fasting — better tolerated and less risk of dehydration
Tirzepatide should not be discontinued during Ramadan in most cases. The appetite-suppressing effect can actually be beneficial during long fasting hours, reducing Iftar overeating. However, individual circumstances vary — always align with your physician before Ramadan.
Frequently Asked Questions
Is tirzepatide (Mounjaro) legal in the UAE?
Yes. Tirzepatide is approved by MOHAP and the Dubai Health Authority for use in the UAE for both type 2 diabetes and chronic weight management. A valid prescription from a UAE-licensed physician is required to purchase it from local clinics or pharmacies.
How much does Mounjaro cost in Dubai?
Monthly costs range from 1,500 AED at the 2.5mg starting dose to 4,299 AED at 10mg through UAE clinics. Clinic prices typically include consultation and follow-up. Original Mounjaro KwikPen (10mg or 15mg) is available from Core Sup at approximately 1,990 AED — significantly below the clinic rate.
How much weight can I realistically lose?
In the SURMOUNT-1 trial, participants lost an average of 15% on 5mg, 20–21% on 10mg, and up to 22.5% on 15mg over 72 weeks. At a starting weight of 90 kg in the UAE context, this equates to 13.5–20 kg of weight loss. Results are significantly better when combined with a reduced-calorie diet and regular exercise.
How long does it take to see results?
Most people notice reduced appetite within the first 1–2 weeks on tirzepatide, even at the 2.5mg starting dose. Meaningful weight loss (2–4 kg) typically appears within the first 4–8 weeks. The most significant weight loss phase is weeks 8–24 as the dose escalates. Weight loss then slows and plateaus as a new equilibrium is reached — usually around week 36–48.
Can I use tirzepatide if I only have 10–15 kg to lose?
Tirzepatide is clinically studied primarily for BMI ≥30 or BMI ≥27 with comorbidities. Individuals with only mild excess weight may find the side effect profile not worth the benefit. Discuss with your physician — lifestyle intervention, dietary changes, or lower-intensity options may be more appropriate for modest weight loss goals.
What happens if I stop taking tirzepatide?
SURMOUNT-4 data showed that participants who discontinued tirzepatide regained an average of 14% of body weight within 52 weeks, effectively reversing most of the weight lost. This reflects the physiological reality that obesity is a chronic condition requiring ongoing treatment. Most physicians treating obesity view tirzepatide as a long-term medication, not a short-term course.
Does tirzepatide affect fertility or is it safe during pregnancy?
Tirzepatide is contraindicated during pregnancy. Animal studies showed adverse effects on fetal development. Women of childbearing age should use effective contraception while on tirzepatide. If you plan to become pregnant, discuss discontinuation timing with your physician — typically at least 2 months before attempting conception. Tirzepatide should also not be used while breastfeeding.
Can tirzepatide be used with intermittent fasting?
Yes, and many users combine tirzepatide with intermittent fasting (16:8 or 18:6 protocols) with positive results. The appetite-suppressing effects of tirzepatide make the fasting window significantly easier to maintain. Ensure adequate protein during your eating window (1.6–2.0g/kg body weight) to minimise lean muscle loss. Avoid combining with extended fasting protocols (36+ hours) without medical supervision.
